Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: LCZ696 (sacubitril/valsartan)

First Posted Date: 2016-09-02

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 794

Registration Number: NCT02887183

Locations: 🇺🇸
Novartis Investigative Site, Tacoma, Washington, United States

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

Phase 3

Completed

Conditions: Chronic Heart Failure (CHF)

Interventions: Drug: LCZ696
Drug: Valsartan
Drug: Placebo of Valsartan
Drug: Placebo of LCZ696

First Posted Date: 2016-08-30

Last Posted Date: 2024-08-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 592

Registration Number: NCT02884206

Locations: 🇬🇧
Novartis Investigative Site, Stevenage, United Kingdom

24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.

Phase 4

Withdrawn

Conditions: Visual Impairment Due to Diabetic Macular Edema

Interventions: Drug: Aflibercept
Drug: Ranibizumab

First Posted Date: 2016-08-25

Last Posted Date: 2017-04-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02878681

Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316

Phase 1

Completed

Conditions: Kidney Transplantation

Interventions: Drug: LFG316
Drug: IVIG

First Posted Date: 2016-08-25

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT02878616

Locations: 🇺🇸
Novartis Investigative Site, Los Angeles, California, United States

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

Phase 4

Completed

Conditions: Heart Failure and Reduced Ejection Fraction

Interventions: Drug: LCZ696 (sacubitril/valsartan)
Drug: Enalapril
Drug: Placebo of Enalapril
Drug: Placebo of LCZ696

First Posted Date: 2016-08-22

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 465

Registration Number: NCT02874794

Locations: 🇺🇸
Novartis Investigative Site, Manitowoc, Wisconsin, United States

Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

Phase 1

Terminated

Conditions: Hepatic Impairment

Interventions: Drug: dabrafenib

First Posted Date: 2016-08-19

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT02873650

Locations: 🇺🇸
American Institute of Research, Los Angeles, California, United States
🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸
Wake Research Associates Oncology, Raleigh, North Carolina, United States

and more 1 locations

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

Phase 1

Completed

Conditions: Macular Edema
Retinal Vein Occlusions
Diabetic Macular Edema
Neovascular Age-related Macular Degeneration

Interventions: Drug: LKA651
Other: Sham Comparator

First Posted Date: 2016-08-16

Last Posted Date: 2022-04-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT02867735

Locations: 🇵🇷
Novartis Investigative Site, Arecibo, Puerto Rico

SCHEDULE Follow Up Visit 5-7 yr

Phase 4

Completed

Conditions: Heart Transplantation

Interventions: Drug: Everolimus
Drug: Cyclosporine
Drug: Mycophenolate mofetil
Drug: Corticosteroids

First Posted Date: 2016-08-12

Last Posted Date: 2019-10-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 95

Registration Number: NCT02864706

Locations: 🇸🇪
Novartis Investigative Site, Lund, Sweden

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: ABL001

First Posted Date: 2016-08-05

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT02857868

Locations: 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
University of Miami / Clinical Research Services, Inc., Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

Phase 2

Terminated

Conditions: Non-alcoholic Steatohepatitis (NASH)

Interventions: Drug: Tropifexor (LJN452)
Drug: Placebo

First Posted Date: 2016-08-04

Last Posted Date: 2021-09-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 350

Registration Number: NCT02855164

Locations: 🇨🇳
Novartis Investigative Site, Taoyuan, Taiwan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy